{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:08:59Z","timestamp":1793052539792,"version":"4.5.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. Its variable course makes it difficult to standardize patient treatment. This article aims at a literature review on available drugs for treating SLE and on drugs that have shown therapeutic effects in this disease. The PubMed\/MEDLINE electronic search engine was used to identify relevant studies. This review presents the current therapeutic options, new biological therapies, and combination therapies of biologics with standard immunosuppressive and immunomodulating drugs. We have also underlined the importance to implement the treat-to-target strategy aimed at reducing or discontinuing therapy with glucocorticosteroids (GCs). The awareness of the benefits and risks of using GCs helps in refining their dosage and thereby obtaining a better safety profile. The advent of biological targeted therapies, and more recently, low-molecular-weight compounds such as kinase inhibitors, initiated numerous clinical trials in SLE patients and led to the approval of two biological drugs, belimumab, and anifrolumab, for SLE treatment. Progress in the treatment of SLE was reflected in the 2019 and 2021 recommendations of the European Alliance of Associations for Rheumatology (EULAR). However, a mass of recent clinical research data requires continuous consolidation to optimize patient outcomes.<\/jats:p>","DOI":"10.1007\/s00296-023-05306-5","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:02:02Z","timestamp":1683849722000},"page":"1395-1407","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":95,"title":["Current treatment of systemic lupus erythematosus: a clinician's perspective"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1982-5980","authenticated-orcid":false,"given":"Pawlak-Bu\u015b","family":"Katarzyna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9409-9827","authenticated-orcid":false,"given":"Schmidt","family":"Wiktor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0175-9441","authenticated-orcid":false,"given":"Dudziec","family":"Ewa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2174-8811","authenticated-orcid":false,"given":"Leszczy\u0144ski","family":"Piotr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"5306_CR1","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1093\/rheumatology\/keu148","volume":"53","author":"I Ruiz-Arruza","year":"2014","unstructured":"Ruiz-Arruza I, Ugarte A, Cabezas-Rodriguez I et al (2014) Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology (Oxford) 53:1470\u20131476. https:\/\/doi.org\/10.1093\/rheumatology\/keu148","journal-title":"Rheumatology (Oxford)"},{"key":"5306_CR2","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1080\/1744666X.2018.1538789","volume":"14","author":"V Ocampo-Piraquive","year":"2018","unstructured":"Ocampo-Piraquive V, Nieto-Aristiz\u00e1bal I, Ca\u00f1as CA et al (2018) Mortality in systemic lupus erythematosus: causes, predictors and interventions. Expert Rev Clin Immunol 14:1043\u20131053. https:\/\/doi.org\/10.1080\/1744666X.2018.1538789","journal-title":"Expert Rev Clin Immunol"},{"key":"5306_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11926-016-0571-2","volume":"18","author":"CE Fors Nieves","year":"2016","unstructured":"Fors Nieves CE, Izmirly PM (2016) Mortality in systemic lupus erythematosus: an updated review. Curr Rheumatol Rep 18:21. https:\/\/doi.org\/10.1007\/s11926-016-0571-2","journal-title":"Curr Rheumatol Rep"},{"key":"5306_CR4","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1136\/annrheumdis-2016-209519","volume":"76","author":"R van Vollenhoven","year":"2017","unstructured":"van Vollenhoven R, Voskuyl A, Bertsias G et al (2017) A framework for remission in SLE: consensus findings from a large international Taskforce on definitions of remission in SLE (DORIS). Ann Rheum Dis 76:554\u2013561. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209519","journal-title":"Ann Rheum Dis"},{"key":"5306_CR5","doi-asserted-by":"publisher","first-page":"e000538","DOI":"10.1136\/lupus-2021-000538","volume":"8","author":"RF van Vollenhoven","year":"2021","unstructured":"van Vollenhoven RF, Bertsias G, Doria A et al (2021) DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med 8:e000538. https:\/\/doi.org\/10.1136\/lupus-2021-000538","journal-title":"Lupus Sci Med"},{"key":"5306_CR6","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","volume":"75","author":"K Franklyn","year":"2016","unstructured":"Franklyn K, Lau CS, Navarra SV et al (2016) Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis 75:1615\u20131621. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207726","journal-title":"Ann Rheum Dis"},{"key":"5306_CR7","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","volume":"73","author":"RF van Vollenhoven","year":"2014","unstructured":"van Vollenhoven RF, Mosca M, Bertsias G et al (2014) Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 73:958\u2013967. https:\/\/doi.org\/10.1136\/annrheumdis-2013-205139","journal-title":"Ann Rheum Dis"},{"key":"5306_CR8","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis A, Kotopoulou M, Alunno A et al (2019) update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78:736\u2013745. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215089","journal-title":"Ann Rheum Dis"},{"key":"5306_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","volume":"80","author":"A Fanouriakis","year":"2021","unstructured":"Fanouriakis A, Tziolos N, Bertsias G et al (2021) Update \u03bfn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis 80:14\u201325. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218272","journal-title":"Ann Rheum Dis"},{"key":"5306_CR10","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.rdc.2021.04.006","volume":"47","author":"SP Canny","year":"2021","unstructured":"Canny SP, Jackson SW (2021) B Cells in systemic lupus erythematosus: from disease mechanisms to targeted therapies. Rheum Dis Clin North Am 47:395\u2013413. https:\/\/doi.org\/10.1016\/j.rdc.2021.04.006","journal-title":"Rheum Dis Clin North Am"},{"key":"5306_CR11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1073\/pnas.79.1.175","volume":"79","author":"HK Ziegler","year":"1982","unstructured":"Ziegler HK, Unanue ER (1982) A decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. Proc Natl Acad Sci USA 79:175\u2013178. https:\/\/doi.org\/10.1073\/pnas.79.1.175","journal-title":"Proc Natl Acad Sci USA"},{"key":"5306_CR12","first-page":"803","volume":"20","author":"K Sperber","year":"1993","unstructured":"Sperber K, Quraishi H, Kalb TH et al (1993) Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells. J Rheumatol 20:803\u2013808","journal-title":"J Rheumatol"},{"key":"5306_CR13","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/ncprheum0292","volume":"2","author":"D Kyburz","year":"2006","unstructured":"Kyburz D, Brentano F, Gay S (2006) Mode of action of hydroxychloroquine in RA\u2014evidence of an inhibitory effect on toll-like receptor signaling. Nat Clin Pract Rheumatol 2:458\u2013459. https:\/\/doi.org\/10.1038\/ncprheum0292","journal-title":"Nat Clin Pract Rheumatol"},{"key":"5306_CR14","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1136\/annrheumdis-2012-202322","volume":"72","author":"N Costedoat-Chalumeau","year":"2013","unstructured":"Costedoat-Chalumeau N, Galicier L, Auma\u00eetre O et al (2013) Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Ann Rheum Dis 72:1786\u20131792. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202322","journal-title":"Ann Rheum Dis"},{"key":"5306_CR15","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.3899\/jrheum.150379","volume":"42","author":"L Durcan","year":"2015","unstructured":"Durcan L, Clarke WA, Magder LS et al (2015) Hydroxychloroquine blood levels in systemic lupus erythematosus: clarifying dosing controversies and improving adherence. J Rheumatol 42:2092\u20132097. https:\/\/doi.org\/10.3899\/jrheum.150379","journal-title":"J Rheumatol"},{"key":"5306_CR16","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJM199101173240303","volume":"324","author":"Canadian Hydroxychloroquine Study Group","year":"1991","unstructured":"Canadian Hydroxychloroquine Study Group (1991) A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 324:150\u2013154. https:\/\/doi.org\/10.1056\/NEJM199101173240303","journal-title":"N Engl J Med"},{"key":"5306_CR17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1191\/096120398678919778","volume":"7","author":"E Tsakonas","year":"1998","unstructured":"Tsakonas E, Joseph L, Esdaile JM (1998) A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 7:80\u201385. https:\/\/doi.org\/10.1191\/096120398678919778","journal-title":"Lupus"},{"key":"5306_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1196\/annals.1422.005","volume":"1108","author":"L Sailler","year":"2007","unstructured":"Sailler L, Puissant B, M\u00e9liani P et al (2007) Blood concentrations of hydroxychloroquine and its desmethyl derivative correlate negatively with the percentage of CD45RO+ cells among CD4+ lymphocytes in hydroxychloroquine-treated lupus patients. Ann N Y Acad Sci 1108:41\u201350. https:\/\/doi.org\/10.1196\/annals.1422.005","journal-title":"Ann N Y Acad Sci"},{"key":"5306_CR19","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1177\/0961203319826693","volume":"28","author":"GS Alarc\u00f3n","year":"2019","unstructured":"Alarc\u00f3n GS, Ugarte-Gil MF, Pons-Estel G et al (2019) Remission and low disease activity state (LDAS) are protective of intermediate and long-term outcomes in SLE patients. Results from LUMINA (LXXVIII), a multiethnic, multicenter US cohort. Lupus 28:423\u2013426. https:\/\/doi.org\/10.1177\/0961203319826693","journal-title":"Lupus"},{"key":"5306_CR20","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1177\/0961203317726376","volume":"27","author":"R Pakchotanon","year":"2018","unstructured":"Pakchotanon R, Gladman DD, Su J et al (2018) Sustained complete renal remission is a predictor of reduced mortality, chronic kidney disease, and end-stage renal disease in lupus nephritis. Lupus 27:468\u2013474. https:\/\/doi.org\/10.1177\/0961203317726376","journal-title":"Lupus"},{"key":"5306_CR21","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1177\/0961203306071872","volume":"15","author":"G Ruiz-Irastorza","year":"2006","unstructured":"Ruiz-Irastorza G, Egurbide MV, Pijoan JI et al (2006) M effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 15:577\u2013583. https:\/\/doi.org\/10.1177\/0961203306071872","journal-title":"Lupus"},{"key":"5306_CR22","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1136\/ard.2006.068676","volume":"66","author":"GS Alarc\u00f3n","year":"2007","unstructured":"Alarc\u00f3n GS, McGwin G, Bertoli AM et al (2007) Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 66:1168\u20131172. https:\/\/doi.org\/10.1136\/ard.2006.068676","journal-title":"Ann Rheum Dis"},{"key":"5306_CR23","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/art.27300","volume":"62","author":"SK Shinjo","year":"2010","unstructured":"Shinjo SK, Bonf\u00e1 E, Wojdyla D et al (2010) Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum 62:855\u2013862. https:\/\/doi.org\/10.1002\/art.27300","journal-title":"Arthritis Rheum"},{"key":"5306_CR24","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/art.24538","volume":"61","author":"GJ Pons-Estel","year":"2009","unstructured":"Pons-Estel GJ, Alarc\u00f3n GS, McGwin G Jr et al (2009) Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Lumina Study Group. Arthritis Rheum 61:830\u2013839. https:\/\/doi.org\/10.1002\/art.24538","journal-title":"Arthritis Rheum"},{"key":"5306_CR25","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/art.39070","volume":"67","author":"CH Feldman","year":"2015","unstructured":"Feldman CH, Hiraki LT, Winkelmayer WC et al (2015) Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. Arthritis Rheum 67:1577\u20131585. https:\/\/doi.org\/10.1002\/art.39070","journal-title":"Arthritis Rheum"},{"key":"5306_CR26","doi-asserted-by":"publisher","first-page":"R109","DOI":"10.1186\/ar2764","volume":"11","author":"G Ruiz-Irastorza","year":"2009","unstructured":"Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I et al (2009) Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther 11:R109. https:\/\/doi.org\/10.1186\/ar2764","journal-title":"Arthritis Res Ther"},{"key":"5306_CR27","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/acr.20133","volume":"62","author":"F Wolfe","year":"2010","unstructured":"Wolfe F, Marmor MF (2010) Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 62:775\u2013784. https:\/\/doi.org\/10.1002\/acr.20133","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"5306_CR28","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","volume":"123","author":"MF Marmor","year":"2016","unstructured":"Marmor MF, Kellner U, Lai T et al (2016) Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 123:1386\u20131394. https:\/\/doi.org\/10.1016\/j.ophtha.2016.01.058","journal-title":"Ophthalmology"},{"key":"5306_CR29","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/2040622310380100","volume":"1","author":"MB Amissah-Arthur","year":"2010","unstructured":"Amissah-Arthur MB, Gordon C (2010) Contemporary treatment of systemic lupus erythematosus: an update for clinicians. Ther Adv Chronic Dis 1:163\u2013175. https:\/\/doi.org\/10.1177\/2040622310380100","journal-title":"Ther Adv Chronic Dis"},{"key":"5306_CR30","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3390\/jcm12020485","volume":"12","author":"H Zhengyan","year":"2023","unstructured":"Zhengyan H, Rui G, Wanrong H et al (2023) Effect of hydroxychloroquine on lupus activity, preeclampsia and intrauterine growth restriction in pregnant women with systemic lupus erythematosus and\/or antiphospholipid syndrome: a systematic review and meta-analysis. J Clin Med 12:485. https:\/\/doi.org\/10.3390\/jcm12020485","journal-title":"J Clin Med"},{"key":"5306_CR31","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/j.jisp.2016.11.001","volume":"18","author":"P Alves","year":"2017","unstructured":"Alves P, Bashir MM, Wysocka M et al (2017) Quinacrine suppresses tumor necrosis factor-\u03b1 and IFN-\u03b1 in dermatomyositis and cutaneous lupus erythematosus. J Investig Dermatol Symp Proc 18:S57-63. https:\/\/doi.org\/10.1016\/j.jisp.2016.11.001","journal-title":"J Investig Dermatol Symp Proc"},{"key":"5306_CR32","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/0049-0172(89)90050-4","volume":"18","author":"DJ Wallace","year":"1989","unstructured":"Wallace DJ (1989) The use of quinacrine (atabrine) in rheumatic diseases: a reexamination. Semin Arthritis Rheum 18:282\u2013296. https:\/\/doi.org\/10.1016\/0049-0172(89)90050-4","journal-title":"Semin Arthritis Rheum"},{"key":"5306_CR33","doi-asserted-by":"publisher","first-page":"7187","DOI":"10.12998\/wjcc.v10.i21.7187","volume":"10","author":"WY Jia","year":"2022","unstructured":"Jia WY, Zhang JJ (2022) Effects of glucocorticoids on leukocytes: genomic and non-genomic mechanisms. World J Clin Cases 10:7187\u20137194. https:\/\/doi.org\/10.12998\/wjcc.v10.i21.7187","journal-title":"World J Clin Cases"},{"key":"5306_CR34","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1093\/rheumatology\/kex444","volume":"57","author":"J Little","year":"2018","unstructured":"Little J, Parker B, Lunt M et al (2018) Glucocorticoid use and factors associated with variability in this use in the systemic lupus international collaborating clinics inception cohort. Rheumatology (Oxford) 57:677\u2013687. https:\/\/doi.org\/10.1093\/rheumatology\/kex444","journal-title":"Rheumatology (Oxford)"},{"key":"5306_CR35","first-page":"1955","volume":"30","author":"DD Gladman","year":"2003","unstructured":"Gladman DD, Urowitz MB, Rahman P et al (2003) Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 30:1955\u20131959","journal-title":"J Rheumatol"},{"key":"5306_CR36","doi-asserted-by":"publisher","first-page":"e000157","DOI":"10.1136\/lupus-2016-000157","volume":"3","author":"D Apostolopoulos","year":"2016","unstructured":"Apostolopoulos D, Kandane-Rathnayake R, Raghunath S et al (2016) Independent association of glucocorticoids with damage accrual in SLE. Lupus Sci Med 3:e000157. https:\/\/doi.org\/10.1136\/lupus-2016-000157","journal-title":"Lupus Sci Med"},{"key":"5306_CR37","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/rheumatology\/kep062","volume":"48","author":"SA Chambers","year":"2009","unstructured":"Chambers SA, Allen E, Rahman A et al (2009) Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology 48:673\u2013675. https:\/\/doi.org\/10.1093\/rheumatology\/kep062","journal-title":"Rheumatology"},{"key":"5306_CR38","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/ncprheum0898","volume":"4","author":"C Stahn","year":"2008","unstructured":"Stahn C, Buttgereit F (2008) Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 4:525\u2013533. https:\/\/doi.org\/10.1038\/ncprheum0898","journal-title":"Nat Clin Pract Rheumatol"},{"key":"5306_CR39","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.3390\/jcm9092709","volume":"9","author":"S Porta","year":"2020","unstructured":"Porta S, Danza A, Arias Saavedra M et al (2020) Glucocorticoids in systemic lupus erythematosus. Ten questions and some issues. J Clin Med 9:2709. https:\/\/doi.org\/10.3390\/jcm9092709","journal-title":"J Clin Med"},{"key":"5306_CR40","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1093\/rheumatology\/ker410","volume":"51","author":"G Ruiz-Irastorza","year":"2012","unstructured":"Ruiz-Irastorza G, Danza A, Khamashta M (2012) Glucocorticoid use and abuse in SLE. Rheumatology 51:1145\u20131153. https:\/\/doi.org\/10.1093\/rheumatology\/ker410","journal-title":"Rheumatology"},{"key":"5306_CR41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.autrev.2017.11.002","volume":"17","author":"L Lightstone","year":"2018","unstructured":"Lightstone L, Doria A, Wilson H et al (2018) Can we manage lupus nephritis without chronic corticosteroid administration? Autoimmun Rev 17:4\u201310. https:\/\/doi.org\/10.1016\/j.autrev.2017.11.002","journal-title":"Autoimmun Rev"},{"key":"5306_CR42","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/acr.23322","volume":"70","author":"I Ruiz-Arruza","year":"2018","unstructured":"Ruiz-Arruza I, Lozano J, Cabezas-Rodriguez I et al (2018) Restrictive use of oral glucocorticoids in systemic lupus erythematosus and prevention of damage without worsening long-term disease control: an observational study. Arthritis Care Res 70:582\u2013591. https:\/\/doi.org\/10.1002\/acr.23322","journal-title":"Arthritis Care Res"},{"key":"5306_CR43","doi-asserted-by":"publisher","first-page":"i114","DOI":"10.1093\/rheumatology\/kew406","volume":"56","author":"D Apostolopoulos","year":"2017","unstructured":"Apostolopoulos D, Morand EF (2017) It hasn\u2019t gone away: the problem of glucocorticoid use in lupus remains. Rheumatology (Oxford) 56:i114\u2013i122. https:\/\/doi.org\/10.1093\/rheumatology\/kew406","journal-title":"Rheumatology (Oxford)"},{"key":"5306_CR44","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/ard.2008.101766","volume":"69","author":"G Ruiz-Irastorza","year":"2010","unstructured":"Ruiz-Irastorza G, Ramos-Casals M, Brito-Zer\u00f3n P et al (2010) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 69:20\u201328. https:\/\/doi.org\/10.1136\/ard.2008.101766","journal-title":"Ann Rheum Dis"},{"key":"5306_CR45","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1002\/art.24068","volume":"59","author":"PR Fortin","year":"2008","unstructured":"Fortin PR, Abrahamowicz M, Ferland D et al (2008) Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 59:1796\u20131804. https:\/\/doi.org\/10.1002\/art.24068","journal-title":"Arthritis Rheum"},{"key":"5306_CR46","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","volume":"71","author":"GK Bertsias","year":"2012","unstructured":"Bertsias GK, Tektonidou M, Amoura Z et al (2012) Joint European League against rheumatism and European renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and pediatric lupus nephritis. Ann Rheum Dis 71:1771\u20131782. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201940","journal-title":"Ann Rheum Dis"},{"key":"5306_CR47","doi-asserted-by":"publisher","first-page":"5517","DOI":"10.1093\/rheumatology\/keab149","volume":"60","author":"L Ji","year":"2021","unstructured":"Ji L, Xie W, Zhang Z (2021) Low-dose glucocorticoids should be withdrawn or continued in systemic lupus erythematosus? A systematic review and meta-analysis on risk of flare and damage accrual. Rheumatology (Oxford) 60:5517\u20135526. https:\/\/doi.org\/10.1093\/rheumatology\/keab149","journal-title":"Rheumatology (Oxford)"},{"key":"5306_CR48","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/acr2.11267","volume":"3","author":"K Tselios","year":"2021","unstructured":"Tselios K, Gladman DD, Su J et al (2021) Gradual glucocorticosteroid withdrawal is safe in clinically quiescent systemic lupus erythematosus. ACR Open Rheumatol 3:550\u2013557. https:\/\/doi.org\/10.1002\/acr2.11267","journal-title":"ACR Open Rheumatol"},{"key":"5306_CR49","doi-asserted-by":"publisher","first-page":"e1002024","DOI":"10.1371\/journal.pmed.1002024","volume":"13","author":"L Fardet","year":"2016","unstructured":"Fardet L, Petersen I, Nazareth I (2016) Common infections in patients prescribed systemic glucocorticoids in primary care: a population-based cohort study. PLoS Med 13:e1002024. https:\/\/doi.org\/10.1371\/journal.pmed.1002024","journal-title":"PLoS Med"},{"key":"5306_CR50","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3389\/fimmu.2020.01732","volume":"29","author":"DY Yap","year":"2018","unstructured":"Yap DY, Lee P, Tam C et al (2018) B cell subsets and signatures in lupus nephritis patients receiving mycophenolate or azathioprine maintenance. J Am Soc Nephrol 29:336. https:\/\/doi.org\/10.3389\/fimmu.2020.01732","journal-title":"J Am Soc Nephrol"},{"key":"5306_CR51","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1002\/art.10461","volume":"46","author":"FA Houssiau","year":"2002","unstructured":"Houssiau FA, Vasconcelos C, D\u2019Cruz D et al (2002) Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46:2121\u20132131. https:\/\/doi.org\/10.1002\/art.10461","journal-title":"Arthritis Rheum"},{"key":"5306_CR52","doi-asserted-by":"publisher","first-page":"CD002922","DOI":"10.1002\/14651858.CD002922.pub4","volume":"6","author":"DJ Tunnicliffe","year":"2018","unstructured":"Tunnicliffe DJ, Palmer SC, Henderson L et al (2018) Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Database Syst Rev 6:CD002922. https:\/\/doi.org\/10.1002\/14651858.CD002922.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"5306_CR53","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.kint.2018.08.025","volume":"95","author":"BH Rovin","year":"2019","unstructured":"Rovin BH, Solomons N, Pendergraft WF et al (2019) A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int 95:219\u2013231. https:\/\/doi.org\/10.1016\/j.kint.2018.08.025","journal-title":"Kidney Int"},{"key":"5306_CR54","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/acr2.11338","volume":"3","author":"J Rubio","year":"2021","unstructured":"Rubio J, Kyttaris V (2021) Journal Club: Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomized, multicenter, placebo-controlled, phase 3 trial. ACR Open Rheumatol 3:827\u2013831. https:\/\/doi.org\/10.1002\/acr2.11338","journal-title":"ACR Open Rheumatol"},{"key":"5306_CR55","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1136\/annrheumdis-2020-217178","volume":"79","author":"C Mok","year":"2020","unstructured":"Mok C, Ho L, Yin S et al (2020) Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis. Ann Rheum Dis 79:1070\u20131076. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217178","journal-title":"Ann Rheum Dis"},{"key":"5306_CR56","first-page":"261","volume":"15","author":"M Rollinghoff","year":"1973","unstructured":"Rollinghoff M, Schrader J, Wagner H (1973) Effect of azathioprine and cytosine arabinoside on humoral and cellular immunity in vitro. Clin Exp Immunol 15:261\u2013269","journal-title":"Clin Exp Immunol"},{"key":"5306_CR57","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/0162-3109(83)90032-2","volume":"6","author":"A Gorski","year":"1983","unstructured":"Gorski A, Korczak-Kowalska G, Nowaczyk M et al (1983) The effect of azathioprine on terminal differentiation of human B lymphocytes. Immunopharmacology 6:259\u2013266. https:\/\/doi.org\/10.1016\/0162-3109(83)90032-2","journal-title":"Immunopharmacology"},{"key":"5306_CR58","doi-asserted-by":"publisher","first-page":"CD007478","DOI":"10.1002\/14651858.CD007478.pub2","volume":"3","author":"CW Hannon","year":"2021","unstructured":"Hannon CW, McCourt C, Lima HC et al (2021) Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev 3:CD007478. https:\/\/doi.org\/10.1002\/14651858.CD007478.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"5306_CR59","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1172\/JCI38010","volume":"119","author":"MP Cancro","year":"2009","unstructured":"Cancro MP, D\u2019Cruz DP, Khamashta MA (2009) The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 119:1066\u20131673. https:\/\/doi.org\/10.1172\/JCI38010","journal-title":"J Clin Invest"},{"key":"5306_CR60","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"S Navarra","year":"2011","unstructured":"Navarra S, Guzman RM, Gallacher AE et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomized, placebo-controlled, phase 3 trial. Lancet 377:721\u2013731. https:\/\/doi.org\/10.1016\/S0140-6736(10)61354-2","journal-title":"Lancet"},{"key":"5306_CR61","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie R, Petri M, Zamani O et al (2011) A Phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63:3918\u20133930. https:\/\/doi.org\/10.1002\/art.30613","journal-title":"Arthritis Rheum"},{"key":"5306_CR62","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"RA Furie","year":"2020","unstructured":"Furie RA, Rovin BH, Joussai F et al (2020) Two-year, randomized controlled trial of belimumab in lupus nephritis. N Engl J Med 383:1117\u20131128. https:\/\/doi.org\/10.1056\/NEJMoa2001180","journal-title":"N Engl J Med"},{"key":"5306_CR63","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.autrev.2017.01.010","volume":"16","author":"S Sciascia","year":"2017","unstructured":"Sciascia S, Radin M, Yazdany J et al (2017) Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: a systematic review. Autoimmun Rev 16:287\u2013293. https:\/\/doi.org\/10.1016\/j.autrev.2017.01.010","journal-title":"Autoimmun Rev"},{"key":"5306_CR64","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1002\/art.21955","volume":"54","author":"S Bernatsky","year":"2006","unstructured":"Bernatsky S, Boivin JF, Joseph L et al (2006) Mortality in systemic lupus erythematosus. Arthritis Rheum 54:2550\u20132557. https:\/\/doi.org\/10.1002\/art.21955","journal-title":"Arthritis Rheum"},{"key":"5306_CR65","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1136\/annrheumdis-2015-207653","volume":"75","author":"DA Isenberg","year":"2016","unstructured":"Isenberg DA, Petri M, Kalunian K et al (2016) Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicenter, randomized, double blind, placebo-controlled study. Ann Rheum Dis 75:323\u2013331. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207653","journal-title":"Ann Rheum Dis"},{"key":"5306_CR66","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/annrheumdis-2015-207654","volume":"75","author":"JT Merrill","year":"2016","unstructured":"Merrill JT, van Vollenhoven RF, Buyon JF et al (2016) Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicenter, randomized, double-blind, placebo-controlled study. Ann Rheum Dis 75:332\u2013340. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207654","journal-title":"Ann Rheum Dis"},{"key":"5306_CR67","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","volume":"74","author":"DA Isenberg","year":"2015","unstructured":"Isenberg DA, Gordon C, Licu D et al (2015) Efficacy and safety of atacicept for prevention of flares in patients with moderate-tosevere systemic lupus erythematosus: 52-week data (APRIL-SLE randomized trial). Ann Rheum Dis 74:2006\u20132015. https:\/\/doi.org\/10.1136\/annrheumdis-2013-205067","journal-title":"Ann Rheum Dis"},{"key":"5306_CR68","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/art.40360","volume":"70","author":"JT Merrill","year":"2018","unstructured":"Merrill JT, Wallace DJ, Wax S et al (2018) Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a 24 week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study. Arthritis Rheumatol 70:266\u2013276. https:\/\/doi.org\/10.1002\/art.40360","journal-title":"Arthritis Rheumatol"},{"key":"5306_CR69","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1093\/rheumatology\/keaa029","volume":"59","author":"E Morand","year":"2020","unstructured":"Morand E, Isenberg DA, Wallace DJ et al (2020) Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase IIb ADDRESS II study. Rheumatology 59:2930\u20132938. https:\/\/doi.org\/10.1093\/rheumatology\/keaa029","journal-title":"Rheumatology"},{"key":"5306_CR70","first-page":"676","volume":"2","author":"P Boross","year":"2012","unstructured":"Boross P, Leusen JH (2012) Mechanisms of action of CD20 antibodies. Am J Cancer Res 2:676\u2013690","journal-title":"Am J Cancer Res"},{"key":"5306_CR71","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ et al (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial (EXPLORER). Arthritis Rheum 62:222\u2013233. https:\/\/doi.org\/10.1002\/art.27233","journal-title":"Arthritis Rheum"},{"key":"5306_CR72","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"BH Rovin","year":"2012","unstructured":"Rovin BH, Furie R, Latinis K et al (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64:1215\u20131226. https:\/\/doi.org\/10.1002\/art.34359","journal-title":"Arthritis Rheum"},{"key":"5306_CR73","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.2215\/CJN.01070118","volume":"13","author":"LM Gomez Mendez","year":"2018","unstructured":"Gomez Mendez LM, Cascino MD, Garg J et al (2018) Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol 13:1502\u20131509. https:\/\/doi.org\/10.2215\/CJN.01070118","journal-title":"Clin J Am Soc Nephrol"},{"key":"5306_CR74","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1136\/ard.2007.083162","volume":"67","author":"D Albert","year":"2008","unstructured":"Albert D, Dunham J, Khan S et al (2008) Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythematosus. Ann Rheum Dis 67:1724\u20131731. https:\/\/doi.org\/10.1136\/ard.2007.083162","journal-title":"Ann Rheum Dis"},{"key":"5306_CR75","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1177\/0961203309106174","volume":"18","author":"M Ramos-Casals","year":"2009","unstructured":"Ramos-Casals M, Soto MJ, Cuadrado MJ et al (2009) Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 18:767\u2013776. https:\/\/doi.org\/10.1177\/0961203309106174","journal-title":"Lupus"},{"key":"5306_CR76","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.semarthrit.2011.06.004","volume":"41","author":"J Narvaez","year":"2011","unstructured":"Narvaez J, Rios-Rodriguez V, de la Fuente D et al (2011) Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence. Semin Arthritis Rheum 41:364\u2013372. https:\/\/doi.org\/10.1016\/j.semarthrit.2011.06.004","journal-title":"Semin Arthritis Rheum"},{"key":"5306_CR77","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1136\/ard.2006.057885","volume":"66","author":"M Tokunaga","year":"2007","unstructured":"Tokunaga M, Saito K, Kawabata D et al (2007) Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 66:470\u2013475. https:\/\/doi.org\/10.1136\/ard.2006.057885","journal-title":"Ann Rheum Dis"},{"key":"5306_CR78","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/TCRM.S252592","volume":"17","author":"A Bag-Ozbek","year":"2021","unstructured":"Bag-Ozbek A, Hui-Yuen JS (2021) Emerging B cell therapies in systemic lupus erythematosus. Ther Clin Risk Manag 17:39\u201354. https:\/\/doi.org\/10.2147\/TCRM.S252592","journal-title":"Ther Clin Risk Manag"},{"key":"5306_CR79","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2019-lsm.98","author":"JT Merrill","year":"2018","unstructured":"Merrill JT, June J, Koumpouras F et al (2018) Top-line results of a phase 2, double-blind, randomized, placebo-controlled study of a reversible B cell inhibitor, XmAb\u00ae5871, in systemic lupus erythematosus (SLE). Lupus Sci Med. https:\/\/doi.org\/10.1136\/lupus-2019-lsm.98","journal-title":"Lupus Sci Med"},{"key":"5306_CR80","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/art.39856","volume":"69","author":"MEB Clowse","year":"2017","unstructured":"Clowse MEB, Wallace DJ, Furie RA et al (2017) Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind, placebo-controlled trials. Arthritis Rheumatol 69:362\u2013375. https:\/\/doi.org\/10.1002\/art.39856","journal-title":"Arthritis Rheumatol"},{"key":"5306_CR81","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/rheumatology\/ket129","volume":"52","author":"DJ Wallace","year":"2013","unstructured":"Wallace DJ, Gordon C, Strand V et al (2013) Efficacy and safety of epratuzumab in patients with moderate\/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicenter studies (ALLEVIATE) and follow-up. Rheumatology 52:1313\u20131322. https:\/\/doi.org\/10.1093\/rheumatology\/ket129","journal-title":"Rheumatology"},{"key":"5306_CR82","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3390\/cells8090963","volume":"8","author":"IT Chyuan","year":"2019","unstructured":"Chyuan IT, Tzeng HT, Chen JY (2019) Signaling pathways of type I and type III Interferons and targeted therapies in systemic lupus erythematosus. Cells 8:963. https:\/\/doi.org\/10.3390\/cells8090963","journal-title":"Cells"},{"key":"5306_CR83","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/art.39962","volume":"69","author":"R Furie","year":"2017","unstructured":"Furie R, Khamashta M, Merrill JT et al (2017) Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol 69:376\u2013386. https:\/\/doi.org\/10.1002\/art.39962","journal-title":"Arthritis Rheumatol"},{"key":"5306_CR84","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand EF, Furie R, Tanaka Y et al (2020) Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 382:211\u2013221. https:\/\/doi.org\/10.1056\/NEJMoa1912196","journal-title":"N Engl J Med"},{"key":"5306_CR85","doi-asserted-by":"publisher","first-page":"381","DOI":"10.4049\/jimmunol.0900939","volume":"183","author":"MM Curtis","year":"2009","unstructured":"Curtis MM, Way SS, Wilson CB (2009) IL-23 promotes the production of IL-17 by antigen-specific CD8 T cells in the absence of IL-12 and type-I interferons. J Immunol 183:381\u2013387. https:\/\/doi.org\/10.4049\/jimmunol.0900939","journal-title":"J Immunol"},{"key":"5306_CR86","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.immuni.2009.08.001","volume":"31","author":"CE Sutton","year":"2009","unstructured":"Sutton CE, Lalor SJ, Sweeney CM et al (2009) Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 31:331\u2013341. https:\/\/doi.org\/10.1016\/j.immuni.2009.08.001","journal-title":"Immunity"},{"key":"5306_CR87","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.3899\/jrheum.210805","volume":"392","author":"R van Vollenhoven","year":"2018","unstructured":"van Vollenhoven R, Hahn BH, Rose S et al (2018) Efficacy and safety of ustekinumab, an interleukin 12\/23 inhibitor, in patients with active systemic lupus erythematosus: results of a phase 2, randomized placebo-controlled study. Lancet 392:1330\u20131339. https:\/\/doi.org\/10.3899\/jrheum.210805","journal-title":"Lancet"},{"key":"5306_CR88","unstructured":"Scaglioni V, Scolnik M, Soriano ER et al (2018) Refractory Lupus Patients: How Frequent Do We See Them in the 21st Century? [Abstract]. Arthritis Rheumatol 70(suppl 9). https:\/\/acrabstracts.org\/abstract\/refractory-lupus-patients-how-frequent-do-we-see-them-in-the-21st-century\/"},{"key":"5306_CR89","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/art.41466","volume":"73","author":"F Atisha","year":"2020","unstructured":"Atisha F, Malkiel S, Harris KM et al (2020) Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthritis Rheumatol 73:121\u2013131. https:\/\/doi.org\/10.1002\/art.41466","journal-title":"Arthritis Rheumatol"},{"key":"5306_CR90","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.7326\/M21-2078","volume":"174","author":"M Shipa","year":"2021","unstructured":"Shipa M, Embleton-Thirsk A, Parvaz M et al (2021) Effectiveness of belimumab after rituximab in systemic lupus erythematosus: a randomized controlled trial. Ann Intern Med 174:1647\u20131657. https:\/\/doi.org\/10.7326\/M21-2078","journal-title":"Ann Intern Med"},{"key":"5306_CR91","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1177\/0961203317691371","volume":"26","author":"C Sj\u00f6wall","year":"2017","unstructured":"Sj\u00f6wall C, Hjorth M, Eriksson P (2017) Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases. Lupus 26:1333\u20131338. https:\/\/doi.org\/10.1177\/0961203317691371","journal-title":"Lupus"},{"issue":"Suppl 1","key":"5306_CR92","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/rheumatology\/key432","volume":"58","author":"M Gadina","year":"2019","unstructured":"Gadina M, Le MT, Schwartz DM et al (2019) Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology (Oxford) 58(Suppl 1):i4\u2013i16. https:\/\/doi.org\/10.1093\/rheumatology\/key432","journal-title":"Rheumatology (Oxford)"},{"key":"5306_CR93","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","volume":"392","author":"DJ Wallace","year":"2018","unstructured":"Wallace DJ, Furie RA, Tanaka Y et al (2018) Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 392:222\u2013231. https:\/\/doi.org\/10.1016\/S0140-6736(18)31363-1","journal-title":"Lancet"},{"key":"5306_CR94","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.2217\/imt-2021-0096","volume":"13","author":"M Gonciarz","year":"2021","unstructured":"Gonciarz M, Pawlak-Bu\u015b K, Leszczy\u0144ski P et al (2021) TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases. Immunotherapy 13:1135\u20131150. https:\/\/doi.org\/10.2217\/imt-2021-0096. (Epub 2021 Jul 8 PMID: 34235974)","journal-title":"Immunotherapy"},{"key":"5306_CR95","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/annrheumdis-2022-eular.5020a","volume":"81","author":"E Morand","year":"2022","unstructured":"Morand E, Pike JT, Merrill R (2022) Efficacy and safety of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with active systemic lupus erythematosus: a phase 2, randomized, double-blind, placebo controlled study. Ann Rheum Dis 81:209. https:\/\/doi.org\/10.1136\/annrheumdis-2022-eular.5020a","journal-title":"Ann Rheum Dis"},{"key":"5306_CR96","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1002\/art.41811","volume":"73","author":"DA Isenberg","year":"2021","unstructured":"Isenberg DA, Furie RA, Jones N et al (2021) Efficacy, safety, and pharmacodynamic effects of the Bruton\u2019s tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 73:1835\u20131846. https:\/\/doi.org\/10.1002\/art.41811","journal-title":"Arthritis Rheum"},{"key":"5306_CR97","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","volume":"74","author":"T Alexander","year":"2015","unstructured":"Alexander T, Sarfert R, Klotsche J et al (2015) The proteasome inhibitor bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis 74:1474\u20131478. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206016","journal-title":"Ann Rheum Dis"},{"key":"5306_CR98","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1080\/14397595.2018.1432331","volume":"28","author":"T Ishii","year":"2018","unstructured":"Ishii T, Tanaka Y, Kawakami A et al (2018) Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus. Mod Rheumatol 28:986\u2013992. https:\/\/doi.org\/10.1080\/14397595.2018.1432331","journal-title":"Mod Rheumatol"},{"key":"5306_CR99","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/PGPM.S205079","volume":"13","author":"E Lever","year":"2020","unstructured":"Lever E, Alves MR, Isenberg DA (2020) Towards precision medicine in systemic lupus erythematosus. Pharmgenomics Pers Med 13:39\u201349. https:\/\/doi.org\/10.2147\/PGPM.S205079","journal-title":"Pharmgenomics Pers Med"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-023-05306-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-023-05306-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-023-05306-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T13:04:56Z","timestamp":1686575096000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-023-05306-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":99,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["5306"],"URL":"https:\/\/doi.org\/10.1007\/s00296-023-05306-5","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]},"assertion":[{"value":"13 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}